Halozyme, Inc.

Yesterday, Halozyme announced the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees. The new patent is licensed under all of Halozyme's ENHANZE® licenses. It will be validated in 37 European countries and expires on March 6, 2029. Halozyme discussed the new European patent and provided an update to its 2024 financial guidance and 5-year financial outlook on a conference call earlier today. To access the webcast and presentation, please visit https://ow.ly/QIQ050Sb7Qt. The press release announcing the patent can be found here: https://ow.ly/s2lW50Sb7Qs

Congrats to David Kang and Michael Travanty for a great session today at American Association of Pharmaceutical Scientists (AAPS) | @aapscomms #NBC2024. Want to learn more about using our ENHANZE platform to develop rapid, large volume subcutaneous injections with a high volume auto-injector (HVAI)? Drop us a comment and a member of our team with reach out!

At American Association of Pharmaceutical Scientists (AAPS) | @aapscomms #NBC2024 this week? Don’t forget to attend our partner presentation on “Recombinant Human Hyaluronidase Facilitated Subcutaneous Drug Delivery Using a 10mL High-Volume Auto-Injector (HVAI)" tomorrow from 11:15 AM – 12:00 PM PT in Learning Lab, Grand Ballroom AB. David Kang and Michael Travanty will be presenting our HVAI design process and exploring the development of a rapid, large volume subcutaneous injections with a HVAI, including the study results for a 10 mL injection of a biologic in less than 30 seconds. Hope to see you there!

ICYMI, earlier this week, we reported financial and operating results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities and outlook. We are pleased to share that we delivered another quarter of double-digit revenue and earnings growth with total revenue increasing 21% year-over-year to $196 million and adjusted EBITDA of $116 million. GAAP diluted earnings per share was $0.60 and non-GAAP diluted EPS was $0.79 in the first quarter. We reiterated 2024 financial guidance and also announced a new $750 million share repurchase program. To view the full press release, click here: https://lnkd.in/gsGq3FCq

Halozyme will be at American Association of Pharmaceutical Scientists (AAPS) | @aapscomms #NBC2024 in San Francisco next week. David Kang and Michael Travanty are presenting on “Recombinant Human Hyaluronidase Facilitated Subcutaneous Drug Delivery Using a 10mL High-Volume Auto-Injector (HVAI)” on Wednesday, May 15, 2024 from 11:15 AM – 12:00 PM PT in Learning Lab, Grand Ballroom AB. Hope to see you at the session, and let us know if you would like to connect while you are at the conference!

Yesterday, Halozyme reported financial and operating results for the fourth quarter and full year ended December 31, 2023. Fourth quarter revenue increased 27% year over year to $230 million with GAAP diluted EPS of $0.65 and non-GAAP diluted EPS of $0.82. Full year 2023 revenue increased 26% year over year to $829 million with GAAP diluted EPS of $2.10 and non-GAAP diluted EPS of $2.77. Halozyme also announced a new $750 million share repurchase program, demonstrating our confidence in sustained and durable growth. https://ow.ly/m8Y650QGczw #Halozyme

Halozyme will host an Investor Business Forum and Long-Term Outlook Call on Wednesday, January 17, 2024 at 5:30 a.m. PT / 8:30 a.m. ET. During the call we will present detailed guidance around the patent dynamics that are expected to drive revenue durability of our ENHANZE® drug delivery technology. The company will also provide 2024 financial guidance as well as long term financial outlook. Register here: https://ow.ly/Zi0050QqaCF

We are excited to announce that Halozyme and Acumen Pharmaceuticals, Inc. have entered a global collaboration and non-exclusive license agreement for the ENHANZE® technology in Alzheimer’s disease. This partnership presents an exceptional opportunity to provide additional treatment options to patients with Alzheimer's disease. According to the World Health Organization, over 55 million people suffer from dementia worldwide, and Alzheimer's disease can be attributed to 60-70% of cases. Our collaboration reinforces our commitment to provide innovative solutions to improve the patient treatment experience, particularly for such a challenging disease in a large patient population. https://ow.ly/Hyyl50Q65fy

Halozyme recently reported our third quarter 2023 financial and operating results, including a 15% year-over-year increase in royalty revenue to a record $114.4 million. "The third quarter was remarkable, with multiple, meaningful, de-risking events and progress for our upcoming series of Wave 3 potential product launches, projected for 2023-2025. I am also pleased with the progress in advancing discussions on development of our HVAI." - Dr. Helen Torley, president and CEO of Halozyme. We are delighted with our strong operating performance and expense management throughout the year and will continue to work toward achieving our 2023 financial and operational goals. #Halozyme https://ow.ly/sFcF50Q659y

Join us and our men’s health experts on Friday, November 17, 2023, for a live product theater at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting in San Diego to learn about different auto-injection and oral delivery testosterone replacement therapy options. We hope to see you there! #Halozyme #SMSNA23 #TRT #MensHealth